12 results on '"Buzón, María José"'
Search Results
2. Impact of very early antiretroviral therapy during acute HIV infection on long-term immunovirological outcomes
- Author
-
Suanzes, Paula, Navarro, Jordi, Rando-Segura, Ariadna, Álvarez-López, Patricia, García, Jorge, Descalzo, Vicente, Monforte, Arnau, Arando, Maider, Rodríguez, Lucía, Planas, Bibiana, Burgos, Joaquín, Curran, Adrian, Buzón, María José, and Falcó, Vicenç
- Published
- 2023
- Full Text
- View/download PDF
3. Mitochondrial dysfunction, lipids metabolism, and amino acid biosynthesis are key pathways for COVID-19 recovery
- Author
-
Sánchez, Alba, García-Pardo, Graciano, Gómez-Bertomeu, Fréderic, López-Dupla, Miguel, Foguet-Romero, Elisabet, Buzón, Maria José, Almirante, Benito, Olona, Montserrat, Fernández-Veledo, Sonia, Vidal, Francesc, Chafino, Silvia, Rull, Anna, and Peraire, Joaquim
- Published
- 2023
- Full Text
- View/download PDF
4. Dextran sulfate from Leuconostoc mesenteroides B512F exerts potent antiviral activity against SARS-CoV-2 in vitro and in vivo
- Author
-
Andreu, Sabina, primary, von Kobbe, Cayetano, additional, Delgado, Pilar, additional, Ripa, Inés, additional, Buzón, María José, additional, Genescà, Meritxell, additional, Gironès, Núria, additional, del Moral-Salmoral, Javier, additional, Ramírez, Gustavo A., additional, Zúñiga, Sonia, additional, Enjuanes, Luis, additional, López-Guerrero, José Antonio, additional, and Bello-Morales, Raquel, additional
- Published
- 2023
- Full Text
- View/download PDF
5. Human lung for the study of SARS-CoV-2
- Author
-
Grau-Expósito, Judith, Perea, David, Suppi, Marina, Massana, Nuria, Vergara, Ander, Soler, María José, Trinité, Benjamin, Blanco, Julià, García-Pérez, Javier, Alcamí, José, Serrano-Mollar, Anna, Rosado, Joel, Falcó, Vicenç, Genesca, Meritxell, Buzón, María José, Generalitat de Catalunya, Instituto de Salud Carlos III, European Commission, Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), Red Española de Investigación en SIDA, Fundació La Marató de TV3, Gilead Sciences, Taller Argal, Buzón, María José, and Buzón, María José [0000-0003-4427-9413]
- Abstract
The development of physiological models that reproduce SARS-CoV-2 infection in primary human cells will be instrumental to identify host-pathogen interactions and potential therapeutics. Here, using cell suspensions directly from primary human lung tissues (HLT), we have developed a rapid platform for the identification of viral targets and the expression of viral entry factors, as well as for the screening of viral entry inhibitors and anti-inflammatory compounds. The direct use of HLT cells, without long-term cell culture and in vitro differentiation approaches, preserves main immune and structural cell populations, including the most susceptible cell targets for SARS-CoV-2; alveolar type II (AT-II) cells, while maintaining the expression of proteins involved in viral infection, such as ACE2, TMPRSS2, CD147 and AXL. Further, antiviral testing of 39 drug candidates reveals a highly reproducible method, suitable for different SARS-CoV-2 variants, and provides the identification of new compounds missed by conventional systems, such as VeroE6. Using this method, we also show that interferons do not modulate ACE2 expression, and that stimulation of local inflammatory responses can be modulated by different compounds with antiviral activity. Overall, we present a relevant and rapid method for the study of SARS-CoV-2., This work was primarily supported by a grant from the Health Department of the Government of Catalonia (DGRIS 1_5). This work was additionally supported in part by the Spanish Health Institute Carlos III (ISCIII, PI17/01470; PI19CIII/00004; PI21CIII/00025 and COV20-00679 (MPY 222-20)), the Spanish Secretariat of Science and Innovation and FEDER funds (grant RTI2018-101082-B-I00 [MINECO/FEDER]), the Spanish AIDS network Red Temática Cooperativa de Investigación en SIDA (RD16/0025/0007 and RD16CIII/0002/0001), the European Regional Development Fund (ERDF), the Fundació La Marató TV3 (grants 201805-10FMTV3 and 201814- 10FMTV3), the Gilead fellowships GLD19/00084 and GLD18/00008 and the Becas Taller Argal 2020. M.J.B is supported by the Miguel Servet program funded by the Spanish Health Institute Carlos III (CP17/00179). N.M. is supported by a Ph.D. fellowship from the Vall d’Hebron Institut de Recerca (VHIR). The funders had no role in study design, data collection and analysis, the decision to publish, or preparation of the manuscript.
- Published
- 2021
6. Fetuin-A, inter-α-trypsin inhibitor, glutamic acid and ChoE (18:0) are key biomarkers in a panel distinguishing mild from critical coronavirus disease 2019 outcomes
- Author
-
Reverté, Laia, Yeregui, Elena, Olona, Montserrat, Gutiérrez Valencia, Alicia, Buzón, María José, Martí, Anna, Gómez-Bertomeu, Frederic, Auguet, Teresa, López-Cortés, Luis F., Burgos, Joaquín, Benavent-Bofill, Clara, Boqué, Carme, García-Pardo, Graciano, Ruiz-Mateos, Ezequiel, Mestre, María Teresa, Vidal, Francesc, Viladés, Consuelo, Peraire, Joaquim, Rull, Anna, COVIDOMICS Study Group, Generalitat de Catalunya, Instituto de Salud Carlos III, European Commission, Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (España), Junta de Andalucía, Consejo Superior de Investigaciones Científicas (España), and Ajuntament de Perafort
- Subjects
Medicine (General) ,R5-920 ,Treatment Outcome ,Alpha-Globulins ,Molecular Medicine ,Medicine (miscellaneous) ,COVID-19 ,Glutamic Acid ,Humans ,Cholesterol Esters ,Severity of Illness Index ,Letter to Editor ,Biomarkers - Abstract
The mechanistic pathways leading to immune dysregulation and complications driven by uncontrolled severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection remain major challenges.1, 2 Hence, a detailed analysis of the proteome, metabolome and lipidome profile of coronavirus disease 2019 (COVID-19) patients showing different severity grades might shed light on the disease pathophysiology and unveil new predictive biomarkers to promptly ascertain patient's outcomes. Our COVID-19 study cohort included 273 SARS-CoV-2 infected individuals recruited during the first wave (March–April 2020) in three different hospitals and grouped by the disease severity following the medical inclusion criteria3 in mild, severe or critical (Figure 1A), from whom demographic, preexisting clinical conditions and COVID-19 treatments are summarized in Table S1. The greatest significant differences were observed between mild and critically ill patients. These findings indicated that older individuals with comorbidities such as hypertension, obesity, diabetes and cardiovascular disorders, mostly presenting dyspnea (Figure 1B), may be at higher risk of suffering from severe respiratory distress with subsequent oxygen and drug requirements and, eventually, died. Similarly, the serum biochemical composition analysis revealed a well-differentiated blood pattern previously defined for critically ill patients (Figure S1)., This work has been developed in the framework of the COVIDOMICS’ project supported by Direcció General de Recerca i Innovació en Salut (DGRIS), Departament de Salut, Generalitat de Catalunya (PoC-6-17 and PoC1-5). The research has also been funded by the Programa de Suport als Grups de Recerca AGAUR (2017SGR948), the SPANISH AIDS Research Network [RD16/0025/0006, RD16/0025/0007 and RD16/0025/0020]-ISCIII-FEDER (Spain), the Centro de Investigación Biomédica en Red de Enfermedades Infecciosas-ISCIII [CB21/13/00020], Madrid, Spain and Consejeria de Transformacion Economica, Industria, Conocimiento y Universidades Junta de Andalucía (research Project CV20-85418). Elena Yeregui was supported by the Instituto de Salud Carlos III (ISCIII) under grant agreement “FI20/00118″ through the programme “Contratos Predoctorales de Formación en Investigación en Salud”. Laia Revertéwas supported by the Instituto de Salud Carlos III (ISCIII) under grant agreement “CD20/00105″ through the programme “Contratos Sara Borrell”. Francesc Vidal was supported by grants from the Programa de Intensificación de Investigadores (INT20/00031)-ISCIII and by “Premi a la Trajectòria Investigadora dels Hospitals de l’ICS 2018″. Anna Rull was supported by a grant from IISPV through the project “2019/IISPV/05″ (Boosting Young Talent), by GeSIDA through the “III Premio para Jóvenes Investigadores 2019″ and by the Instituto de Salud Carlos III (ISCIII) under grant agreement “CP19/00146″ through the Miguel Servet Program. Maria José Buzón was supported by the Miguel Servet Program (CP17/00179). Ezequiel Ruiz- Mateos was supported by the Spanish Research Council (CSIC). Alicia Gutiérrez-Valencia was supported by the Instituto de Salud Carlos III, cofinanced by the European Development Regional Fund (“A way to achieve Europe”), Subprograma Miguel Servet (grant CP19/00159). This project was also funded by a donation from the city Council of Perafort (to Teresa Auguet).
- Published
- 2022
7. Contribution of Immunological and Virological Factors to Extremely Severe Primary HIV Type 1 Infection
- Author
-
Dalmau, Judith, Puertas, Maria Carmen, Azuara, Marta, Mariño, Ana, Frahm, Nicole, Mothe, Beatriz, Izquierdo-Useros, Nuria, Buzón, Maria José, Paredes, Roger, Matas, Lourdes, Allen, Todd M., Brander, Christian, Rodrigo, Carlos, Clotet, Bonaventura, and Martinez-Picado, Javier
- Published
- 2009
- Full Text
- View/download PDF
8. Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure
- Author
-
Codoñer, Francisco M., Pou, Christian, Thielen, Alexander, García, Federico, Delgado, Rafael, Dalmau, David, Santos, José Ramon, Buzón, Maria José, Martínez-Picado, Javier, Álvarez-Tejado, Miguel, Clotet, Bonaventura, Ruiz, Lidia, and Paredes, Roger
- Published
- 2010
- Full Text
- View/download PDF
9. Executive summary of the GeSIDA consensus document on control and monitoring of HIV-infected patients
- Author
-
Crespo, Manuel, Lozano, Fernando, Buzón, María José, Curran, Adria, Estrada Pérez, Vicente, García, Federico, Imaz, Arkaitz, López-Cortés, Luis F., Losa, Juan Emilio, Masia, Mar, Merchante, Nicolás, Mariño, Ana, Ocampo-Sosa, Alain Antonio, Pérez-Molina, José A., Riera, Melchor, Santin, Miguel, Santos, Jesús, Valencia, Eulalia, Arazo, Piedad, Torre, Javier de la, López-Aldeguer, José, Palacios, Rosario, Rubio, Rafael, Sanz, José, Téllez, María Jesús, and Poveda, Eva
- Subjects
Adult ,0301 basic medicine ,Microbiology (medical) ,Anti-HIV Agents ,Substance-Related Disorders ,030106 microbiology ,Sexually Transmitted Diseases ,Emigrants and Immigrants ,HIV Infections ,Comorbidity ,Guidelines ,Recommendations ,03 medical and health sciences ,0302 clinical medicine ,Latent Tuberculosis ,Neoplasms ,Humans ,Lymphocyte Count ,Viremia ,030212 general & internal medicine ,Consensus document ,Early Detection of Cancer ,Human immunodeficiency virus ,Liver Diseases ,Mental Disorders ,Vaccination ,Guías ,Disease Management ,Viral Load ,Documento de consenso ,Virus de la inmunodeficiencia humana ,GeSIDA ,Cardiovascular Diseases ,Acquired immune deficiency syndrome ,Recomendaciones ,Patient Compliance ,Kidney Diseases ,Síndrome de inmunodeficiencia adquirida - Abstract
AIDS Study Group (GeSIDA) of the Spanish Society of Infectious Diseases and Clinical Microbiology, [EN] The continuous increase in our knowledge of HIV medicine and antiretroviral treatment has led us to draft specific consensus documents focused on topics other than antiretroviral therapy, such as treatment of opportunistic diseases, pre- and post-exposure prophylaxis, metabolic abnormalities, treatment of HBV or HCV coinfection, treatment of patients coinfected with tuberculosis, osteoporosis, kidney disorders, and cardiovascular risk. Accordingly, the AIDS Study Group (GeSIDA) of the Spanish Society of Infectious Diseases and Clinical Microbiology has promoted the drafting of this consensus document on the control and monitoring of adult patients infected with HIV. The document provides recommendations on the initial evaluation and subsequent monitoring of HIV-infected patients that will prove useful for all professionals involved in the management of this infection., [ES] La complejidad creciente de los conocimientos relativos a la infección por el VIH y al tratamiento antirretroviral (TAR) ha condicionado la elaboración de documentos de consenso específicos que abordan aspectos diferentes al TAR. Son ejemplos, la profilaxis y el tratamiento de las infecciones oportunistas, la profilaxis post y pre-exposición, las alteraciones metabólicas y el riesgo cardiovascular, la osteoporosis, los trastornos renales, la co-infección por el VHB y el VHC o el manejo de este en pacientes con tuberculosis, entre otros. En esta línea, la Junta Directiva de GeSIDA ha promovido la elaboración de un documento de consenso sobre el control y la monitorización de los adultos infectados por el VIH. El objetivo de este documento es proporcionar una serie de recomendaciones sobre la evaluación inicial y la posterior monitorización clínica de los pacientes infectados por el VIH, que pueda servir como referencia para todos los profesionales implicados en el cuidado de estos pacientes.
- Published
- 2019
10. Episomal HIV-1 DNA and its relationship to other markers of HIV-1 persistence
- Author
-
Martinez-Picado, Javier, primary, Zurakowski, Ryan, additional, Buzón, María José, additional, and Stevenson, Mario, additional
- Published
- 2018
- Full Text
- View/download PDF
11. Integrated and Total HIV-1 DNA Predict Ex Vivo Viral Outgrowth
- Author
-
Kiselinova, Maja, De Spiegelaere, Ward, Buzon, Maria Jose, Malatinkova, Eva, Lichterfeld, Mathias, and Vandekerckhove, Linos
- Subjects
Biology and Life Sciences ,Microbiology ,Medical Microbiology ,Microbial Pathogens ,Viral Pathogens ,Immunodeficiency Viruses ,HIV ,HIV-1 ,Medicine and Health Sciences ,Pathology and Laboratory Medicine ,Pathogens ,Organisms ,Viruses ,Biology and life sciences ,RNA viruses ,Retroviruses ,Lentivirus ,Molecular Biology ,Molecular Biology Techniques ,Artificial Gene Amplification and Extension ,Polymerase Chain Reaction ,Genetics ,DNA ,DNA replication ,Biochemistry ,Nucleic acids ,Virology ,Viral Replication ,Biological Cultures ,Cell Culture Analysis ,Outgrowth Assay ,Cell Biology ,Cellular Types ,Animal Cells ,Blood Cells ,White Blood Cells ,T Cells ,Immune Cells ,Immunology ,Viral Persistence and Latency - Abstract
The persistence of a reservoir of latently infected CD4 T cells remains one of the major obstacles to cure HIV. Numerous strategies are being explored to eliminate this reservoir. To translate these efforts into clinical trials, there is a strong need for validated biomarkers that can monitor the reservoir over time in vivo. A comprehensive study was designed to evaluate and compare potential HIV-1 reservoir biomarkers. A cohort of 25 patients, treated with suppressive antiretroviral therapy was sampled at three time points, with median of 2.5 years (IQR: 2.4–2.6) between time point 1 and 2; and median of 31 days (IQR: 28–36) between time point 2 and 3. Patients were median of 6 years (IQR: 3–12) on ART, and plasma viral load (<50 copies/ml) was suppressed for median of 4 years (IQR: 2–8). Total HIV-1 DNA, unspliced (us) and multiply spliced HIV-1 RNA, and 2LTR circles were quantified by digital PCR in peripheral blood, at 3 time points. At the second time point, a viral outgrowth assay (VOA) was performed, and integrated HIV-1 DNA and relative mRNA expression levels of HIV-1 restriction factors were quantified. No significant change was found for long- and short-term dynamics of all HIV-1 markers tested in peripheral blood. Integrated HIV-1 DNA was associated with total HIV-1 DNA (p<0.001, R² = 0.85), us HIV-1 RNA (p = 0.029, R² = 0.40), and VOA (p = 0.041, R2 = 0.44). Replication-competent virus was detected in 80% of patients by the VOA and it correlated with total HIV-1 DNA (p = 0.039, R² = 0.54). The mean quantification difference between Alu-PCR and VOA was 2.88 log10, and 2.23 log10 between total HIV-1 DNA and VOA. The levels of usHIV-1 RNA were inversely correlated with mRNA levels of several HIV-1 restriction factors (TRIM5α, SAMHD1, MX2, SLFN11, pSIP1). Our study reveals important correlations between the viral outgrowth and total and integrated HIV-1 DNA measures, suggesting that the total pool of HIV-1 DNA may predict the size of the replication-competent virus in ART suppressed patients.
- Published
- 2016
- Full Text
- View/download PDF
12. Potent Cell-Intrinsic Immune Responses in Dendritic Cells Facilitate HIV-1-Specific T Cell Immunity in HIV-1 Elite Controllers
- Author
-
Martin-Gayo, Enrique, Buzon, Maria Jose, Ouyang, Zhengyu, Hickman, Taylor, Cronin, Jacqueline, Pimenova, Dina, Walker, Bruce D., Lichterfeld, Mathias, and Yu, Xu G.
- Abstract
The majority of HIV-1 elite controllers (EC) restrict HIV-1 replication through highly functional HIV-1-specific T cell responses, but mechanisms supporting the evolution of effective HIV-1-specific T cell immunity in these patients remain undefined. Cytosolic immune recognition of HIV-1 in conventional dendritic cells (cDC) can facilitate priming and expansion of HIV-1-specific T cells; however, HIV-1 seems to be able to avoid intracellular immune recognition in cDCs in most infected individuals. Here, we show that exposure of cDCs from EC to HIV-1 leads to a rapid and sustained production of type I interferons and upregulation of several interferon-stimulated effector genes. Emergence of these cell-intrinsic immune responses was associated with a reduced induction of SAMHD1 and LEDGF/p75, and an accumulation of viral reverse transcripts, but inhibited by pharmacological blockade of viral reverse transcription or siRNA-mediated silencing of the cytosolic DNA sensor cGAS. Importantly, improved cell-intrinsic immune recognition of HIV-1 in cDCs from elite controllers translated into stronger abilities to stimulate and expand HIV-1-specific CD8 T cell responses. These data suggest an important role of cell-intrinsic type I interferon secretion in dendritic cells for the induction of effective HIV-1-specific CD8 T cells, and may be helpful for eliciting functional T cell immunity against HIV-1 for preventative or therapeutic clinical purposes.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.